BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abutaleb NS, Seleem MN. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection. Sci Rep 2020;10:7701. [PMID: 32382070 DOI: 10.1038/s41598-020-64882-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen J, Du Y, Lu Y, Wang H, Wu Q. Recent development of small-molecular inhibitors against Clostridioides difficile infection. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.105843] [Reference Citation Analysis]
2 Wang S, Deng W, Li F, Chen YE, Wang PU. Blockade of T helper 17 cell function ameliorates recurrent Clostridioides difficile infection in mice. Acta Biochim Biophys Sin (Shanghai) 2021:gmab107. [PMID: 34379099 DOI: 10.1093/abbs/gmab107] [Reference Citation Analysis]
3 Mohammad H, Abutaleb NS, Dieterly AM, Lyle LT, Seleem MN. Investigating auranofin for the treatment of infected diabetic pressure ulcers in mice and dermal toxicity in pigs. Sci Rep 2021;11:10935. [PMID: 34035383 DOI: 10.1038/s41598-021-90360-x] [Reference Citation Analysis]
4 Chen J, Li Y, Wang S, Zhang H, Du Y, Wu Q, Wang H. Targeting Clostridioides difficile: new uses for old drugs. Drug Discov Today 2022:S1359-6446(22)00131-3. [PMID: 35390545 DOI: 10.1016/j.drudis.2022.03.021] [Reference Citation Analysis]
5 Yamashita M. Auranofin: Past to Present, and repurposing. Int Immunopharmacol 2021;101:108272. [PMID: 34731781 DOI: 10.1016/j.intimp.2021.108272] [Reference Citation Analysis]
6 Ndugire W, Raviranga NGH, Lao J, Ramström O, Yan M. Gold Nanoclusters as Nanoantibiotic Auranofin Analogues. Adv Healthc Mater 2021;:e2101032. [PMID: 34350709 DOI: 10.1002/adhm.202101032] [Reference Citation Analysis]
7 Monaghan TM, Seekatz AM, Mullish BH, Moore-Gillon CCER, Dawson LF, Ahmed A, Kao D, Chan WC. Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opin Ther Targets 2021;:1-15. [PMID: 34793686 DOI: 10.1080/14728222.2021.2008907] [Reference Citation Analysis]
8 Abutaleb NS, Elkashif A, Flaherty DP, Seleem MN. In Vivo Antibacterial Activity of Acetazolamide. Antimicrob Agents Chemother 2021;65:e01715-20. [PMID: 33495225 DOI: 10.1128/AAC.01715-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Naclerio GA, Abutaleb NS, Li D, Seleem MN, Sintim HO. Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence In Vivo. J Med Chem 2020;63:11934-44. [PMID: 32960605 DOI: 10.1021/acs.jmedchem.0c01198] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Abutaleb NS, Seleem MN. In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection. Sci Rep 2021;11:7093. [PMID: 33782498 DOI: 10.1038/s41598-021-86595-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Felix L, Mylonakis E, Fuchs BB. Thioredoxin Reductase Is a Valid Target for Antimicrobial Therapeutic Development Against Gram-Positive Bacteria. Front Microbiol 2021;12:663481. [PMID: 33936021 DOI: 10.3389/fmicb.2021.663481] [Reference Citation Analysis]
12 Abutaleb NS, Elhassanny AEM, Flaherty DP, Seleem MN. In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci. PeerJ 2021;9:e11059. [PMID: 33850651 DOI: 10.7717/peerj.11059] [Cited by in F6Publishing: 2] [Reference Citation Analysis]